Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 139 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gemzar and Alimta Clear all
Suspended Phase 1Phase 2 Interventional

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT06694454
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Alimta Plus Gemcitabine for Advanced Sarcoma

NCT00860015
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Alimta, Gemcitabine
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

NCT01447225
View directory record Official record
Conditions
Solid Tumors
Interventions
MM-121, Carboplatin, Pemetrexed, Cabazitaxel, Gemcitabine
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Lafayette, Indiana • Buffalo, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 2, 2026, 5:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617
View directory record Official record
Conditions
Medulloblastoma
Interventions
Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine, Aerobic Training, Neurocognitive Remediation
Radiation · Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
14
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 2, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT01935947
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Docetaxel, Entinostat, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 2, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 2, 2026, 5:21 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

NCT06632327
View directory record Official record
Conditions
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
415
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Recruiting Phase 1 Interventional

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

NCT04701645
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

GSK1120212 Rollover Study

NCT01376310
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212, Pemetrexed + GSK1120212, Carboplatin + GSK1120212, Nab-paclitaxel + GSK1120212, Gemcitabine + GSK1120212, Everolimus + GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Results available

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

NCT01358968
View directory record Official record
Conditions
Cancer
Interventions
LY2603618, Desipramine, Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

NCT00111839
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
Pemetrexed, Matuzumab
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

NCT03085914
View directory record Official record
Conditions
Solid Tumor
Interventions
Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 2, 2026, 5:21 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180
View directory record Official record
Conditions
Cervical Cancer
Interventions
Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
38
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

NCT00456261
View directory record Official record
Conditions
Lung Cancer
Interventions
Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
70 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

NCT00059865
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
41
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

NCT02409342
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
9
States / cities
La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00407550
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine HCL, pemetrexed disodium
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 2, 2026, 5:21 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

NCT03918278
View directory record Official record
Conditions
Neoplasms
Interventions
MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 2, 2026, 5:21 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma NSCLC
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
35
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

NCT06865339
View directory record Official record
Conditions
NSCLC, Locally Advanced
Interventions
Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC)
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 2, 2026, 5:21 AM EDT
Terminated Phase 3 Interventional Results available

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

NCT00863512
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 2, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 2, 2026, 5:21 AM EDT